Onyx Therap patents expiration
1. Kyprolis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7232818 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US8207297 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US8207125 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US7417042 | ONYX THERAP | Compounds for enzyme inhibition |
Jul, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207127 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US8129346 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US7491704 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US8207126 | ONYX THERAP | Compounds for enzyme inhibition |
Apr, 2025
(1 year, 6 months from now) | |
| US7737112 | ONYX THERAP | Composition for enzyme inhibition |
Dec, 2027
(4 years from now) | |
| USRE47954 | ONYX THERAP | Combination therapy with peptide epoxyketones |
Oct, 2029
(6 years from now) | |
| US9511109 | ONYX THERAP | Combination therapy with peptide epoxyketones |
Oct, 2029
(6 years from now) | |
| US9493582 | ONYX THERAP | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
Market Authorisation Date: 20 July, 2012
Treatment: Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 ...
Dosage: POWDER;INTRAVENOUS
KYPROLIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic